logo
Plus   Neg
Share
Email

Ligand Pharma Acquires Economic Rights To PTX-022 From Palvella For $10 Mln

Ligand Pharmaceuticals Inc. (LGND) Monday said it acquired economic rights to PTX-022 from Palvella Therapeutics.

PTX-022 is a novel, topical formulation of rapamycin currently in Phase 2/3 development for the treatment of pachyonychia congenita, a rare skin disorder for which no FDA-approved treatment exists.

Ligand will pay $10 million to Palvella Therapeutics and in return will receive a tiered royalty on net sales in the mid-to-upper single digits, as well as regulatory and financing milestones. Ligand will not incur any expenses to develop or commercialize PTX-022.

Pachyonychia congenita is a serious, chronically debilitating genetic disorder that results in malformation of the skin and severely limits the mobility and quality-of-life of those affected. PTX-022 has received Fast Track and Orphan Drug designations from the FDA.

"This transaction provides Palvella Therapeutics with capital to complete its planned clinical trials that could be the basis for registration and approval of a novel and important new medicine," said John Higgins, Chief Executive Officer of Ligand.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Crate and Barrel have recalled 1,500 push walkers due to risk of choking and laceration. Crate and Barrel have recalled Activity Push Walkers as those walkers can be damaged over time exposing sharp points and small parts, posing choking and laceration hazards to small children. The wooden recalled... YouTube is finalizing plans under which it will no longer serve "targeted" advertisements on its main site for videos meant for kids, Bloomberg reported, citing people familiar with the discussion. While the plan is reportedly intended to satisfy U.S. regulators, it could negatively impact the Google-owned video giant's ad sales as kids' content on YouTube is immensely popular. Apple Inc. (AAPL) is in the final stages of certifying advanced flexible Organic Light Emitting Diode or OLED screens from Chinese display maker BOE Technology Group for iPhones next year, the Nikkei Asian Review reported citing source. The U.S. tech giant has been attempting to reduce reliance on Samsung Electronics of South Korea.
Follow RTT